Acrux Limited (ACR) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 42 PAGES: 47

Acrux Limited (Acrux) is a Australia-based company, which carries out the manufacture, development and distribution of a range of patient-preferred, patented pharmaceutical products. Its product pipeline consists of treatment of hormonal deficiencies, central nervous system disorders, contraception and dermatological conditions. The company's products find application in the treatment of menopausal symptoms, chronic pain, hormonal deficiencies, central nervous system disorders, contraception and dermatological conditions. Acrux combines its platform technologies, Across, Mdts and Patchless Patch to develop its products.

More Info
									          Acrux Limited (ACR) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDME5098FSA                                                                                           Publication Date: MAR 2013

          103-113   Stanley           Street,      West
                                                             Phone              +61 3 83790100                  Revenue          10.71 (million AUD)
          Melbourne
          Melbourne, VIC                                     Fax                +61 3 83790101                  Net Profit       7.39 (million AUD)
          3003                                               Website            www.acrux.com.au                Employees        43
                                                                                ACR [Australian Stock
          Australia                                          Exchange                                           Industry         Medical Equipment
                                                                                Exchange (Sydney)]

       Company Overview
       Acrux Limited (Acrux) is a Australia-based company, which carries out the manufacture, development and distribution of a range
       of patient-preferred, patented pharmaceutical products. Its product pipeline consists of treatment of hormonal deficiencies, central
       nervous system disorders, contraception and dermatological conditions. The company's products find application in the treatment
       of menopausal symptoms, chronic pain, hormonal deficiencies, central nervous system disorders, contraception and
       dermatological conditions. Acrux combines its platform technologies, Across, Mdts and Patchless Patch to develop its products.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Acrux Limited, SWOT Analysis
         Ross Dobinson                       Chairman                                 Strengths                              Weaknesses
         Bruce Parncutt                      Director
                                                                                      Manufacturing Alliance with            Operational Inefficiency
         Ross Barrow                         Director                                 Orion
         Jon Pilcher                         Chief Financial Officer
                                                                                      Acrux’s Platform Technologies
         Clive Blower, Ph.D.                 Chief Technology Officer
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Emerging Markets                       Uncertain R&D Outcomes
         Acrux Limited
                                                                                      New Product Approvals and              Competitive Landscape
        Share Price (AUD) as on 08-Mar-                                     4         Launches
        2013
        EPS (AUD)                                                        0.04
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million AUD)                                         666         GlobalData

        Enterprise Value (million AUD)                                   647
        Shares Outstanding (million)                                     167
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 22, 2012         Acrux Announces Board Changes
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Acrux Limited (ACR) - Financial and Strategic SWOT Analysis                                                                     Reference Code: GDME5098FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Acrux Limited - Key Facts................................................................................................................................................................... 5
       Acrux Limited - Key Employees.......................................................................................................................................................... 6
       Acrux Limited - Key Employee Biographies........................................................................................................................................ 7
       Acrux Limited - Major Products and Services ..................................................................................................................................... 8
       Acrux Limited - Pharmaceutical Pipeline Products Data..................................................................................................................... 9
          Acrux Limited, Pipeline Products by Therapy Area ......................................................................................................................... 9
          Acrux Limited, Pipeline Products by Development Phase ............................................................................................................ 10
       Acrux Limited - History ..................................................................................................................................................................... 22
       Acrux Limited - Company Statement ................................................................................................................................................ 24
       Acrux Limited - Locations And Subsidiaries ..................................................................................................................................... 25
          Head Office ................................................................................................................................................................................... 25
          Other Locations & Subsidiaries ..................................................................................................................................................... 25
       Section 2 – Company Analysis ......................................................................................................................................................... 26
       Acrux Limited - Business Description ............................................................................................................................................... 26
       Acrux Limited - Corporate Strategy .................................................................................................................................................. 27
       Acrux Limited - SWOT Analysis ....................................................................................................................................................... 28
          SWOT Analysis - Overview........................................................................................................................................................... 28
          Acrux Limited - Strengths.............................................................................................................................................................. 28
             Strength - Manufacturing Alliance with Orion ............................................................................................................................ 28
             Strength - Acrux’s Platform Technologies ................................................................................................................................. 28
             Strength - Strong liquidity .......................................................................................................................................................... 28
          Acrux Limited - Weaknesses ........................................................................................................................................................ 28
             Weakness - Operational Inefficiency ......................................................................................................................................... 28
          Acrux Limited - Opportunities........................................................................................................................................................ 29
             Opportunity - Emerging Markets ............................................................................................................................................... 29
             Opportunity - New Product Approvals and Launches ................................................................................................................ 29
             Opportunity - Growing Aged Population .................................................................................................................................... 29
          Acrux Limited - Threats ................................................................................................................................................................. 29
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 29
             Threat - Competitive Landscape ............................................................................................................................................... 30
             Threat - Stringent Regulations .................................................................................................................................................. 30
       Acrux Limited - Key Competitors ...................................................................................................................................................... 31
       Section 3 – Company Financial Ratios ............................................................................................................................................. 32
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 32
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 32
       Performance Chart ........................................................................................................................................................................... 34
       Financial Performance...................................................................................................................................................................... 34
       Financial Ratios - Interim Ratios....................................................................................................................................................... 35
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 36
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 37
          Acrux Limited, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ...................................................................... 37


Acrux Limited (ACR) - Financial and Strategic SWOT Analysis                                                                                                     Reference Code: GDME5098FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Acrux Limited, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................
								
To top